Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer
Ozge Saatci,Rashedul Alam,Kim-Tuyen Huynh-Dam,Aynur Isik,Meral Uner,Nevin Belder,Pelin Gulizar Ersan,Unal Metin Tokat,Burge Ulukan,Metin Cetin,Kubra Calisir,Mustafa Emre Gedik,Hilal Bal,Ozlem Sener Sahin,Yasser Riazalhosseini,Denis Thieffry,Daniel Gautheret,Besim Ogretmen,Sercan Aksoy,Aysegul Uner,Aytekin Akyol,Ozgur Sahin
DOI: https://doi.org/10.1038/s41419-024-06814-3
2024-06-16
Cell Death and Disease
Abstract:Tamoxifen has been the mainstay therapy to treat early, locally advanced, and metastatic estrogen receptor-positive (ER + ) breast cancer, constituting around 75% of all cases. However, the emergence of resistance is common, necessitating the identification of novel therapeutic targets. Here, we demonstrated that long-noncoding RNA LINC00152 confers tamoxifen resistance by blocking tamoxifen-induced ferroptosis, an iron-mediated cell death. Mechanistically, inhibiting LINC00152 reduces the mRNA stability of phosphodiesterase 4D ( PDE4D ), leading to activation of the cAMP/PKA/CREB axis and increased expression of the TRPC1 Ca 2+ channel. This causes cytosolic Ca 2+ overload and generation of reactive oxygen species (ROS) that is, on the one hand, accompanied by downregulation of FTH1, a member of the iron sequestration unit, thus increasing intracellular Fe 2+ levels; and on the other hand, inhibition of the peroxidase activity upon reduced GPX4 and xCT levels, in part by cAMP/CREB. These ultimately restore tamoxifen-dependent lipid peroxidation and ferroptotic cell death which are reversed upon chelating Ca 2+ or overexpressing GPX4 or xCT. Overexpressing PDE4D reverses LINC00152 inhibition-mediated tamoxifen sensitization by de-activating the cAMP/Ca 2+ /ferroptosis axis. Importantly, high LINC00152 expression is significantly correlated with high PDE4D/low ferroptosis and worse survival in multiple cohorts of tamoxifen- or tamoxifen-containing endocrine therapy-treated ER+ breast cancer patients. Overall, we identified LINC00152 inhibition as a novel mechanism of tamoxifen sensitization via restoring tamoxifen-dependent ferroptosis upon destabilizing PDE4D, increasing cAMP and Ca 2+ levels, thus leading to ROS generation and lipid peroxidation. Our findings reveal LINC00152 and its effectors as actionable therapeutic targets to improve clinical outcome in refractory ER+ breast cancer.
cell biology